CommercialCoverageMedium impact
06.02.54c, Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing
Independence Blue Cross·Internal Medicine, Family Medicine, Hematology +3 more·Medical Policy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Policy 06.02.54c regarding Cobalamin (Vitamin B12), Folic Acid, and Homocysteine Testing was reissued effective 11/26/2025. Without access to the full policy text content, the specific billing impacts, coverage changes, or prior authorization requirements cannot be determined. The billing team must immediately obtain and review the complete policy document to identify any changes from the previous version.
Action Required
By 11/26/2025: Billing team must obtain the complete policy text from the URL provided (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=11&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-06-02-54c) and compare it against the previous version of policy 06.02.54c to identify specific changes. Review for: (1) CPT/HCPCS codes affected (e.g., 82607, 82746, 83090 for B12/folic acid/homocysteine testing), (2) new prior authorization requirements, (3) coverage restrictions or limitations, (4) documentation requirements. Update billing software, encounter templates, and provider alerts accordingly based on findings. Failure to implement changes by the effective date may result in claim denials or payment delays.